What is Slomag (Verapamil)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 16, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

What is Slomag (Verapamil)?

Slomag is a brand name for verapamil, a non-dihydropyridine calcium channel blocker used primarily for cardiovascular conditions including hypertension, angina, and cardiac arrhythmias. 1

Mechanism of Action

Verapamil works by inhibiting calcium influx through L-type calcium channels in arterial smooth muscle and cardiac cells, which produces several key effects 1:

  • Vasodilation: Decreases systemic vascular resistance by dilating peripheral arterioles, leading to blood pressure reduction without typically causing orthostatic hypotension or reflex tachycardia 1
  • Cardiac effects: Produces negative inotropic (reduced contractility), chronotropic (reduced heart rate), and dromotropic (slowed AV conduction) effects 2
  • Coronary vasodilation: Dilates coronary arteries and is a potent inhibitor of coronary artery spasm 1

Primary Clinical Indications

Arrhythmias

  • Supraventricular tachycardia: First-line treatment for stable, narrow-complex tachycardias when adenosine or vagal maneuvers fail, dosed at 2.5-5 mg IV over 2 minutes 3
  • Atrial fibrillation/flutter rate control: 5-10 mg IV every 15-30 minutes to a total of 20-30 mg for acute control 3, 4
  • Long-term rate control: 120-480 mg daily in divided doses or as sustained-release formulation 5, 4

Angina Pectoris

  • Effective for vasospastic (Prinzmetal's) angina and stable angina 5, 1
  • Initial dose: 120 mg daily, maintenance up to 480 mg daily 5

Hypertension

  • Effective first-line treatment for mild to moderate essential hypertension 1, 6
  • Particularly useful in elderly patients and those with contraindications to beta-blockers (e.g., asthma, COPD) 6

Critical Contraindications

Absolute contraindications include 5, 3:

  • Second- or third-degree AV block without a pacemaker
  • Severe sinus node dysfunction without a pacemaker
  • Decompensated systolic heart failure or severe left ventricular dysfunction
  • Cardiogenic shock or severe hypotension
  • Wolff-Parkinson-White syndrome with atrial fibrillation/flutter
  • Recent beta-blocker use (risk of profound bradycardia and hypotension)
  • Concomitant use with dofetilide (contraindicated) 5

Common Adverse Effects

The most frequent side effects include 5, 3, 2:

  • Constipation (most common)
  • Hypotension
  • Bradycardia
  • Leg edema
  • Worsening heart failure in patients with pre-existing ventricular dysfunction
  • AV block
  • Pulmonary edema in hypertrophic cardiomyopathy patients 5

Important Drug Interactions

Verapamil is a moderate CYP3A4 inhibitor and P-glycoprotein inhibitor, leading to significant interactions 5:

  • Contraindicated: Dofetilide 5
  • Requires dose adjustment: Digoxin (reduce by 30-50%), simvastatin, dabigatran, edoxaban, rivaroxaban 5
  • Avoid: Grapefruit juice (increases verapamil levels) 5
  • Caution with: Other AV nodal blocking agents, ivabradine 2

Formulations and Dosing

Immediate-Release

  • Available as 120 mg, 180 mg, and 240 mg tablets 1
  • Typically dosed 3-4 times daily for cardiovascular indications 7

Sustained-Release

  • Allows once-daily dosing up to 240 mg; higher doses may require twice-daily administration 8
  • Designed for sustained release in the gastrointestinal tract 1
  • Tablets can be divided in half without altering sustained-release characteristics 1

Clinical Pearls

  • Monitoring: Regular assessment of heart rate, blood pressure, and ECG for AV conduction abnormalities is essential during therapy 4
  • Elderly patients: Consider lower initial doses due to altered pharmacokinetics 4
  • Renal/hepatic impairment: Dose adjustments may be necessary 4
  • Bradycardia threshold: Heart rate less than 50 beats/min is uncommon (1.4% incidence) 1

References

Guideline

Calcium Channel Blocker Pharmacology

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Verapamil Indications and Usage

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Verapamil Dosage for Rate Control

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Sustained-release verapamil formulations for treating hypertension.

Journal of clinical pharmacology, 1992

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.